Physician profile
David Reed
NPI 1912945791
$8,689.88
in general payments reported to CMS, 2019-2025
24 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,566 · 2020: $729 · 2021: $758 · 2022: $24.75 · 2023: $4,250 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,500 · Food and Beverage: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,500.00 |
| Food and Beverage | $112.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verathon INC. | $4,500.00 | 2023-2025 | Npd Clinical Study & Bronchoscope, Npd Clinical Study |
| Boston Scientific Corporation | $1,076.70 | 2019 | |
| Ferring Pharmaceuticals INC. | $425.36 | 2019-2021 | |
| Astellas Pharma US INC | $391.66 | 2019-2021 | |
| Janssen Biotech, INC. | $274.23 | 2019-2020 | |
| Amgen INC. | $255.05 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $240.76 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $240.09 | 2019-2020 | |
| Abbvie INC. | $213.39 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $211.10 | 2019-2025 | |
| Pfizer INC. | $184.47 | 2019-2021 | |
| Myovant Sciences INC. | $159.72 | 2021 | |
| 180 Medical, INC. | $97.26 | 2020-2021 | |
| Coloplast Corp | $61.72 | 2019-2020 | |
| Rochester Medical Corporation | $58.15 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $53.20 | 2020-2021 | |
| Dentsply Ih Ab | $50.20 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $39.46 | 2020 | |
| Dentsply Ih INC. | $38.19 | 2020 | |
| Myriad Genetic Laboratories, INC. | $36.79 | 2020-2021 | |
| Urogen Pharma, INC. | $24.92 | 2021 | |
| Urovant Sciences INC | $24.75 | 2022 | |
| Laborie Medical Technologies Corp. | $16.40 | 2020 | |
| Teleflex LLC | $16.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.